Explore this article's sources with AI
Follow PeptideMethods on Google
Semaglutide in Youths With Autism
A retrospective cohort linked semaglutide with greater weight reductions in youths with autism and obesity, but only 20 received treatment.
Why we wrote this. The paper concerns an understudied pediatric population, but its small exposed group and observational design need to stay beside the result.
In this article (5 sections)
A 2026 real-world paper on semaglutide in youths with autism spectrum disorder and obesity reported greater reductions in two weight measures among those documented as receiving semaglutide. The analysis was a retrospective cohort subanalysis, not a randomized trial. Only 20 of 120 youths received semaglutide, so the result is an early observational signal rather than proof of a treatment effect[1].
The indexed record describes youths aged 12 years or older who had autism spectrum disorder and obesity and were receiving multidisciplinary obesity care. Semaglutide exposure meant that the record documented weekly dosing of at least 0.5 mg. That threshold defines the exposed group in this analysis. It is not a dosing recommendation[2].
How the retrospective cohort was analyzed
Researchers examined changes in percentage of the 95th percentile for BMI, written as %BMIp95, along with body weight and BMI z-score. They also assessed percentage body fat and cardiometabolic laboratory values. %BMIp95 expresses BMI relative to the pediatric 95th percentile. The abstract does not report a single prespecified primary endpoint, raw average changes for every outcome, or the follow-up period in months[1].
The investigators used multivariable linear regression. Their model adjusted for each outcome's baseline value and for age, sex, race, insurance, stimulant use, and atypical antipsychotic use. Other anti-obesity medicines and follow-up duration were also included. Adjustment can reduce imbalance in measured factors. It cannot account for every unrecorded difference between the 20 treated youths and the 100 who did not receive semaglutide[2].
Treatment was chosen during routine care rather than assigned by the researchers. The groups may therefore have differed in clinical need, family preference, ability to use an injectable medicine, or prior treatment response. Follow-up may also have differed, as could other factors not captured by the model. Multidisciplinary care means that semaglutide was part of a broader care setting rather than an isolated intervention.
What the semaglutide results mean
Semaglutide exposure was associated with a regression coefficient of -8.11 for change in %BMIp95, with a p value of 0.006. For body weight, the coefficient was -7.61 kg, with a p value of 0.003[1]. In the fitted model, those negative coefficients indicate greater reductions associated with the semaglutide group after the listed adjustments. They should not be read as guaranteed losses for an individual youth.
The coefficients also are not the same as a randomized difference. A p value describes how compatible the fitted result is with a null association under the model's assumptions. It does not measure the chance that semaglutide caused the change, and it does not correct for selection into treatment or unknown confounders.
The paper also reported a trend toward lower alanine aminotransferase, or ALT, with a p value of 0.053[2]. This did not meet the conventional 0.05 threshold used for the two reported weight findings. The abstract gives no effect estimate for ALT and does not establish a liver benefit. It does not report significant results for BMI z-score or body fat percentage. Nor does it report significant results for the other laboratory outcomes named in the methods.
Why the pediatric and autism context matters
The authors began from a specific evidence gap: anti-obesity medication data in youths with autism spectrum disorder are limited. Their cohort addresses that population directly rather than transferring an adult obesity result to children and adolescents[1]. Even so, the semaglutide group contained only 20 youths. A small exposed group limits precision and makes it harder to examine whether outcomes differed by age, sex, concurrent medicines, or support needs.
Autism spectrum disorder covers varied communication profiles, health needs, and daily support. The abstract does not describe those characteristics, how treatment acceptability was assessed, or whether sensory and behavioral factors affected continuation. It also does not report patient-centered outcomes such as quality of life, daily functioning, treatment burden, or caregiver experience. Weight measures alone cannot answer those questions.
For broader evidence and medicine information, the semaglutide research overview separates controlled trials from observational reports. This paper belongs in the latter category. Its value is that it describes routine multidisciplinary care in a population with little direct evidence. Its main weakness is the same feature: treatment and follow-up occurred outside random assignment.
What the abstract does not establish
No PubMed Central full text was available when this readout was prepared, and the publisher full text was not substantively accessible from this environment. The indexed abstract does not disclose the study site count, recruitment dates, actual follow-up duration, baseline group table, missing-data pattern, semaglutide dose distribution, treatment persistence, or reasons for starting and stopping. This article therefore does not infer any of those details.
The abstract also does not report adverse events. It cannot show that semaglutide was well tolerated in this cohort, identify uncommon harms, or compare safety with no semaglutide. The absence of a safety result in the abstract is an evidence gap, not evidence that no adverse events occurred. Questions about contraindications and monitoring require the full prescribing information and clinical assessment.
What we don't yet know
A prospective study could define treatment and follow-up in advance, record discontinuations, capture adverse events, and include outcomes chosen with autistic youths and families. A randomized design would be needed to estimate a causal treatment effect with much stronger protection against selection bias. Larger enrollment would also allow more credible subgroup analyses.
For now, the defensible conclusion is narrow. In a retrospective subanalysis of 120 youths with autism spectrum disorder and obesity, the 20 with documented semaglutide exposure had greater adjusted reductions in %BMIp95 and weight. The study does not establish how much a particular young person would lose, whether the association was caused by semaglutide, or how benefits compare with harms over time.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Was this a randomized semaglutide trial?
No. It was a retrospective cohort subanalysis of youths receiving multidisciplinary obesity care. Treatment was documented in clinical records rather than assigned at random.
How many youths received semaglutide?
Twenty of 120 youths, or 16.7%, had documented semaglutide exposure. The other 100 did not, making the exposed group small for drawing broad conclusions.
Did the paper establish semaglutide safety in autistic youths?
No. The indexed abstract does not report adverse events, discontinuations, or a safety comparison. It therefore cannot establish tolerability or identify uncommon harms in this population.
Sources
No revisions yet. First published .